


## PHARMACEUTICAL 2022

## MACROGENICS INC Rank 343 of 475







## PHARMACEUTICAL 2022

## MACROGENICS INC Rank 343 of 475



The relative strengths and weaknesses of MACROGENICS INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of MACROGENICS INC compared to the market average is the variable Revenues, increasing the Economic Capital Ratio by 51% points. The greatest weakness of MACROGENICS INC is the variable Research and Development, reducing the Economic Capital Ratio by 195% points.

The company's Economic Capital Ratio, given in the ranking table, is -259%, being 18% points above the market average of -276%.

| Input Variable                              | Value in 1000 USD |
|---|-------------------|
| Assets, Current                             | 279,560           |
| Cost of Goods Sold                          | 2,651             |
| Intangible Assets                           | 0                 |
| Liabilities, Current                        | 74,578            |
| Liabilities, Non-Current                    | 21,049            |
| Other Assets                                | 18,009            |
| Other Compr. Net Income                     | -54               |
| Other Expenses                              | 0                 |
| Other Liabilities                           | 0                 |
| Other Net Income                            | 680               |
| Property and Equipment                      | 37,676            |
| Research and Development                    | 214,577           |
| Revenues                                    | 77,447            |
| Selling, General and Administrative Expense | 63,014            |

| Output Variable          | Value in 1000 USD |
|--------------------------|-------------------|
| Assets                   | 335,245           |
| Liabilities              | 95,627            |
| Expenses                 | 280,242           |
| Stockholders Equity      | 239,618           |
| Net Income               | -202,115          |
| Comprehensive Net Income | -202,142          |
| Economic Capital Ratio   | -259%             |